Goran Micevic
YOU?
Author Swipe
View article: Supplementary Figure 5 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Supplementary Figure 5 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity Open
CD8+ T cells reduce GPX4 expression in melanoma cells to promote ferroptosis
View article: Data from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Data from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity Open
Identifying factors that mediate successful anticancer immune responses is necessary to improve outcomes for patients with advanced cancers. In this study, we performed single-cell RNA sequencing on mouse melanomas experiencing successful …
View article: Supplementary Figure 2 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Supplementary Figure 2 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity Open
CD8+ T cells induce cancer cell lipid peroxidation and ferroptosis
View article: Supplementary Figure 1 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Supplementary Figure 1 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity Open
scRNA-seq of tumors undergoing immune cell-mediated clearance reveals a ferroptosis signature
View article: Supplementary Figure 3 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Supplementary Figure 3 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity Open
Ferroptosis is a driver of immune-mediated tumor clearance ex vivo and in vivo
View article: Supplementary Figure 6 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Supplementary Figure 6 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity Open
scRNA-seq of human tumors responsive to immunotherapy confirms a ferroptosis signature
View article: Supplementary Figure 4 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Supplementary Figure 4 from Cytotoxic CD8<sup>+</sup> T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity Open
Direct co-culture of CD8+ T cells and cancer cells leads to cancer cell death
View article: EGFR-STAT1 pathway drives fibrosis initiation in fibroinflammatory skin diseases
EGFR-STAT1 pathway drives fibrosis initiation in fibroinflammatory skin diseases Open
Chronic inflammatory skin diseases affect the health of millions of people worldwide, and those that feature fibrosis are refractory to treatments. The signals that determine whether fibrosis occurs during chronic skin inflammation are poo…
View article: Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma Open
Importance Tumor-infiltrating lymphocytes (TILs) are a provocative biomarker in melanoma, influencing diagnosis, prognosis, and immunotherapy outcomes; however, traditional pathologist-read TIL assessment on hematoxylin and eosin–stained s…
View article: DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities
DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities Open
View article: Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge
Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge Open
BACKGROUNDImmune checkpoint blockade (ICB) is an effective treatment in a subset of patients diagnosed with head and neck squamous cell carcinoma (HNSCC); however, the majority of patients are refractory.METHODSIn a nonrandomized, open-lab…
View article: Engineering Mice to Study Human Immunity
Engineering Mice to Study Human Immunity Open
Humanized mice, which carry a human hematopoietic and immune system, have greatly advanced our understanding of human immune responses and immunological diseases. These mice are created via the transplantation of human hematopoietic stem a…
View article: Figure S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S5: Evaluation of SETDB1 knockdown in human melanoma cells, related to Figure 4:
View article: Figure S6 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S6 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S6: Characterization of possible SKO tumor antigens, related to Figure 4.
View article: Table S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Differential expression of SKO vs YRG cells ± IFNAR blockade by RNAseq.
View article: Figure S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S4: Evaluation of differences in SKO tumor gene expression and microenvironment profiles, related to Figure 3:
View article: Table S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Ranked CRISPR screen dropout hits, related to Figure 1. Analysis was performed using MaGeCK.
View article: Data from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Data from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators of immunity to melanoma, we performed a whole-genome CRISPR screen in melano…
View article: Table S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Differential expression of SKO vs YRG cells, by RNAseq.
View article: Figure S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S1: Experimental validation of SETDB1 knockout and flow gating schemes, related to Figure 4
View article: Figure S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S2: CRISPR screen guide distributions, related to Figure 1
View article: Figure S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S3: Validation and characterization of Setdb1-/- cell lines, tumors, and microenvironments, related to Figure 2.
View article: Table S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Summary of exonic mutations in YRG cells compared with YMG and WT C57BL6/J cells.
View article: Table S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
List of primers used to perform RT-qPCR on YUDOSO cells related to Figure S6.
View article: Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis
Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis Open
A woman with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis presented to our hospital with hepatic encephalopathy, acute kidney injury, and painful skin lesions. A skin biopsy and broad work-up led to a diagnosis of non-…
View article: Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas
Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas Open
Although the vast majority of CTCL subtypes are of the CD4+ T-helper cell differentiation phenotype, there is a spectrum of CD8+ variants that manifest wide-ranging clinical, histologic, and phenotypic features that inform the classificati…
View article: Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours
Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours Open
Two decades ago, the median survival for metastatic melanoma was only 5-9 months (1).Breakthroughs in research and clinical trials have spearheaded the approval of targeted therapies (BRAF-and MEK-inhibitors) and immune checkpoint inhibito…
View article: Cutaneous diatoms from diatomaceous earth mimicking myiasis infection
Cutaneous diatoms from diatomaceous earth mimicking myiasis infection Open
View article: 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma
1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma Open
Background Recurrence of advanced melanoma after checkpoint therapy is a major risk factor for death, and treatment options are limited. Anti-tumor memory plays a critical role in preventing recurrence, but the identity, location and funct…
View article: New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events
New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events Open
Cutaneous side-effects associated with immune checkpoint blockade occur in more than half of patients treated with CTLA-4 and PD-1 inhibitors, and are frequently encountered by dermatologists. The molecular mechanism of cutaneous side-effe…